Abstract.-The effects of a variety of pharmacological and physiological manipulations on the activity of hepatic tyrosine transaminase have been extensively investigated. Brain tyrosine transaminase, however, has received only limited attention. Since tyrosine transaminase may be important in the regulation of catecholamine biosynthesis in the brain, the effects of agents affecting catecholamine storage and synthesis on brain tyrosine transamination were investigated. Transamination in the 12,000 X g fraction was measured by a radioactive procedure. a-Methyltyrosine and reserpine, agents which deplete brain catecholamines, decreased tyrosine transaminase activity. Administration of the catecholamine precursor, L-3,4-dihydroxyphenylalanine to the reserpineand a-methyltyrosine-treated rats elevated the tyrosine transaminase activity to normal. The possible implications of these findings in the regulation of the biosynthesis of the catecholamines are discussed.
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Tyrosine transaminase activity in the liver has been extensively investigated. Hepatic tyrosine transaminase exhibits a number of fascinating characteristics which have stimulated considerable interest in this enzyme. Its activity is rapidly and markedly induced by a variety of physiological and pharmacological manipulations including age,' corticosteroids,2' pancreatic hormones,4 and psychopharmacological agents.5-In contrast, brain tyrosine transaminase has received relatively little attention. Early studies by Canellakis and Cohen8 revealed minimal tyrosine transaminase activity in dog brain. Fonnum et al. 9 and Fonnum and Larsen'0 presented evidence for three different aromatic amino acid transferases in the brain. Subsequently, George and Gabay" reported a procedure for a 900-fold purification of an aromatic amino acid transferase from pig brain cortex and investigated certain kinetic properties of the enzyme.
Since catecholamines are formed from tyrosine and since the availability of this catecholamine precursor could conceivably be affected by transamination, it seemed pertinent to investigate this enzyme iii the brain where catecholamine biosynthesis is of particular interest.
Tyrosine transamination can be conveniently measured by a radioactive procedure and was found to be markedly decreased by drugs known to decrease catecholamine levels in the brain. Administration of L-3,4-dihydroxyphenylalanine (L-DOPA),T which is known to replenish catecholamines, returned the tyrosine transamination to normal.
Materials and Methods.-Male, Sprague-Dawley, 180-to 220-gm rats were fed Purina Chow ad libitum until the particular drug was administered. At that time all food was withheld from the onset of the experiment until the time of sacrificing.
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The animals were sacrificed by decapitation after which the brains were quickly removed and homogenized in 4 volumes of chilled 0.32 M sucrose solution containing EDTA (10-s M) and dithiothreitol (10-3 M). Particles obtained from centrifugation at 12,000 X g for 15 min were used for all enzyme determinations unless otherwise indicated. The mitochondrial pellet was resuspended in the sucrose mixture and sonicated for 40 sec at 40C with a Bronson 75 W sonifier at maximum power (10 kc).
Brain tyrosine transaminase activity was assayed by a modification of the method of Wurtman and Larin.12 The standard reaction mixture contained potassium phosphate buffer (pH 7.6; 300 Mmoles), -tyrosine (7.5 /imoles), a-ketoglutarate (15,umoles) , pyridoxal phosphate (60 mjmoles), EDTA (1.5 Mumoles), diethyldithiocarbamate (6 smoles), 1 ,c L-3,5-H'-ditritiotyrosine (25 c/mmole) and enzyme in a final volume of 1.5 ml. All components of the reaction mixture except a-ketoglutarate were preincubated for 10 min before the a-ketoglutarate was added to start the reaction. After incubation at 37CC for 1 hr, the reaction was stopped by the addition of 0.5 ml of 6 X HCl. A 1-ml aliquot of the deaminated radioactive material was extracted into 6 ml of a mixture of toluene and isoamyl alcohol (9:1). The organic phase was washed with 1 nll of 1 N HC1. A 4-ml aliquot was transferred to a vial and counted in a Packard Tri-Carb liquid scintillation spectrometer after the addition of 2 ml ethanol and 10 ml phosphor (0.4% 2,5-diphenyloxazole and 0.005% 1,4-di(2,5-phenyloxazole)benzene in toluene). About 80% of the H3-p-hydroxyphenylpyruvate was recovered by this extraction. Less than 1% of H3-tyrosine remained in the organic solvent. The appropriate correction was made for the amount of H3-tyrosine by running zero-time blanks.
Protein was estimated by the method of Aldridge"3 with crystalline bovine serum albumin as a standard. Results.-Tyrosine transaminase activity has been studied primarily in the liver. Hepatic tyrosine transaminase activity is localized predominantly in the 105,000 X g microsomal supernatant fluid.14 In contrast to the liver, fractionation of brain cells revealed that tyrosine transaminase is localized in the mitochondrial fraction (12,000 X g particles) with a similar amount sedimenting in the 500 X g fraction. The 12,000 X g particles were used in all experiments reported.
The possibility that brain tyrosine transaminase is bound to the particles sedimenting at 12,000 X g was then explored. Sonication of this brain fraction for varying time periods revealed an increase in enzyme activity that was maximal after 40 seconds with the system described (Fig. 1) . The enzyme preparation was therefore sonicated for 40 seconds in all experiments.
The rate of formation of p-hydroxyphenylpyruvate (pHPP) was followed and found to be linear over a two-hour period (Fig. 2) . All studies were carried out with an incubation time of one hour.
The effect of enzyme concentration on the rate of pHPP formation is shown in Figure 3 . The rate was linear up to 0.1 ml of enzyme (0.85 mg of protein). With enzyme concentrations above 0.85 mg, the rate of formation of product began to fall off slightly. Wurtman and Larin2 and George and Gabay" found a very high Km for tyrosine transaminase (-3.0 X 10-31). Since this concentra- tion parallels the solubility of tyrosine at 37aC, it is impossible to obtain optimal substrate levels for enzyme assay. At higher enzyme concentrations the velocity of the reaction may decrease because of an inadequate tyrosine concentration. Tyrosine transaminase activity was determined at three enzyme concentrations, 0.05, 0.1, and 0.2 ml (0.43, 0.85, and 1.7 mg of protein, respectively) in the drug investigations to ensure that a linear response was obtained.
The effect of reserpine, a depletor of biogenic amines, on brain tyrosine transaminase was examined (Fig. 4) . Brain tyrosine transaminase activity was decreased to 60 per cent of normal,-(P < 0.0005) after reserpine was administered.
Reserpine not only depletes brain norepinephrine but also decreases 5-hydroxytryptamine levels in the brain. a-M\lethyl-para-tyrosine (a-MIT) inhibits tyrosine hydroxylase, 15 the rate-limiting step in the biosynthesis of norepinephrine from tyrosine.16 Administration of a-M\IT therefore causes selective depletion of norepinephriiie, while the 5-hydroxytryptamine stores remain at normal levels. Depletion of brain norepinephrine with a-MAIT caused a marked decrease in brain tyrosine trlans.aminase activity similar to that caused by reserpine (Table 1 Norepinephrine stores may be returned toward normal by administration of L-DOPA, a precursor of norepinephrine capable of crossing the blood-brain barrier. Administration of L-DOPA to rats previously depleted of norepinephrine either by reserpine or by a-M\IT returned the brain tyrosine transaminase levels to normal, reversing the effects of the depletors of brain norepinephrine (Fig. 4 and Table 1 ).
Discussion.-MAuch attention and investigation have been focused on the biosynthetic enzymes involved in the conversion of tyrosine to the catecholamines aRd the effects exerted on this conversion by the catecholamines themselves and by agents that influence their endogenous levels. Tyrosine occupies an important regulatory position in the metabolic pathway of related aromatic amino acids in that it can be hydroxylated and converted to catecholamines or, alternatively, transaminated to p-hydroxyphenylpyruvate (pHPP) and subsequently converted to catabolic products. It is quite possible that brain tyrosine transaminase activity can affect the amount of tyrosine available for hydroxylation, as can be seen by a comparison of the activities of tyrosine transaminase and tyrosine hydroxylase in the brain. Nagatsu et al. 17 found that tyrosine hydroxylase in rat brain homogenate generated 8.1 mlimole of L-DOPA per gram of brain per hour. In the experiments reported herein, tyrosine transaminase in the 12,000 X g particles formed 812 mpumole of pHPP per gram of brain per hour. These data indicate that tyrosine transaminase in the rat brain is capable of transaminating tyrosine to pHPP at a rate which is one hundred times greater than the rate at which tyrosine is hydroxylated to -DOPA. It would be feasible to postulate from these observations that tyrosine transamination could play a significant role in regulating catecholamine biosynthesis.
The data of Figure 4 and Table 1 lend credence to the possibility that tyrosine transaminase activity is altered by catecholamines levels. Both reserpine and a-MT, substances that deplete brain catecholamines,7 dramatically decreased the tyrosine transaminase activity. It is possible that a regulatory mechanism (e.g., low levels of catecholamines) is acting to "turn off" transamination and thereby shunts more tyrosine through the hydroxylation step to replenish the catecholamine stores. Conversely, repletion of the catecholamine levels by administration of the catecholamine precursor, L-DOPA, elevated tyrosine transamination to normal. This would agree with the suggested hypothesis, since it would be anticipated that normal levels of catecholamines would shunt more tyrosine into the transamination pathway because less would be required for formation of catecholamines.
The possibility that catecholamines can regulate tyrosine levels by acting on tyrosine transaminase is being further explored by the infusion of labeled tyrosine into the rat to determine the amount of label incorporated into pHPP and into its subsequent degradation products, after administration of agents that alter catecholamine levels.
The effect of reserpine and a-MT on brain tyrosine transaminase activity is directly opposite to that on hepatic tyrosine transamination. Many investigators'-7 have observed that reserpine markedly increases hepatic tyrosine transaminase activity. Wurtman et al. '8 suggested that this effect of reserpine may be explained by a change in the eating habits of the reserpine-treated rats. Axelrod and Black,'9 on the other hand, presented evidence to suggest that the level of brain catecholamines alters hepatic tyrosine transaminase activity. They showed that ,B-phenylisopropylhydrazine (Catron), a monoamine oxidase inhibitor, suppressed the hepatic tyrosine transaminase activity. By depleting brain catecholamines with reserpine or a-MT, Black and Axelrod7 observed the opposite effect, that is, an increase in hepatic tyrosine transaminase activity. These investigators found that repletion of brain norepinephrine by administration of L-DOIPA decreased hepatic tyrosine transaminase to normal. Depletion of brain catecholamines, then, increases hepatic tyrosine transaminase activity7 but decreases brain tyrosine transaminase activity (Fig. 4 and Table 1 ). The alteration of brain tyrosine transaminase by brain catecholamine levels could conceivably be a mechanism whereby the brain levels of tyrosine available for hydroxylation and, hence, synthesis of brain catecholamines could be regulated. 
